An example of the therapeutic use of targeting AATs is exemplified by JPH203 (nanvuranlat), an inhibitor of the large amino acid transporter LAT1 (SLC7A5), which is currently in clinical trials for the treatment of biliary tract cancer [4]. Here, SLC7A5 is linked to biliary tract cancer.